within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04B_Urologicals.G04BD10_Darifenacin;

model Darifenacin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.19,
    Cl = 1.1111111111111112e-05,
    adminDuration = 600,
    adminMass = 15 / 1000000,
    adminCount = 1,
    Vd = 0.163,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.002,
    Tlag = 720,
    Vdp = 0.353,
    k12 = 1.1944444444444446e-05,
    k21 = 1.1944444444444446e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Darifenacin</td></tr><tr><td>ATC code:</td><td>G04BD10</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>15</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>163</td><td>L</td></tr>
    <tr><td>clearance:</td><td>40</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Darifenacin is a selective muscarinic M3 receptor antagonist used to treat symptoms of overactive bladder, such as urinary incontinence, urgency, and frequency. It is approved for clinical use and is commonly administered orally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers after repeated oral administration.</p><h4>References</h4><ol><li><p>Kerbusch, T, et al., &amp; Karlsson, MO (2003). Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. <i>British journal of clinical pharmacology</i> 56(6) 639–652. DOI:<a href=\"https://doi.org/10.1046/j.1365-2125.2003.01967.x\">10.1046/j.1365-2125.2003.01967.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14616424/\">https://pubmed.ncbi.nlm.nih.gov/14616424</a></p></li><li><p>McFerren, SC, &amp; Gomelsky, A (2015). Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin. <i>Drugs &amp; aging</i> 32(10) 809–819. DOI:<a href=\"https://doi.org/10.1007/s40266-015-0301-x\">10.1007/s40266-015-0301-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26391900/\">https://pubmed.ncbi.nlm.nih.gov/26391900</a></p></li><li><p>Kerbusch, T, et al., &amp; Karlsson, MO (2004). Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. <i>British journal of clinical pharmacology</i> 57(2) 170–180. DOI:<a href=\"https://doi.org/10.1046/j.1365-2125.2003.01988.x\">10.1046/j.1365-2125.2003.01988.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14748816/\">https://pubmed.ncbi.nlm.nih.gov/14748816</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G04BD10 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Darifenacin;
